CD8A and glioblastoma: MIF additionally downregulates natural killer group 2 member D receptor (NKG2D) on both NK cells and CD8+ T lymphocytes to reduce their tumoricidal activity.84 Glioblastoma stem cells secrete MIF to activate CXCR2, prompting MDSCs to inhibit CD8+ T lymphocytes.74